Elevated intracranial pressure (ICP) is a primary cause of morbidity and mortality for many neurologic disorders. The relationship between ICP and brain volume is influenced by autoregulatory processes that can become dysfunctional. As a result, neurologic damage can occur by systemic and intracranial insults such as ischemia and excitatory amino acids. Therefore, survival is dependent on optimizing ICP and cerebral perfusion pressure. Treatment of intracranial hypertension requires intensive monitoring and aggressive therapy. Intracranial pressure monitoring techniques such as intraventricular catheters are useful for determining ICP elevations before changes in vital signs and neurologic status. Therapeutic modalities, generally aimed at reducing cerebral blood volume, brain tissue, and cerebrospinal fluid (CSF) volume, include nonpharmacologic (CSF removal, controlled hyperventilation, and elevating the patient’s head) and pharmacologic management. Mannitol and sedation are first-line agents used to lower ICP. Barbiturate coma may be beneficial in patients with elevated ICP refractory to conventional treatment. The use of prophylactic antiseizure therapy and optimal nutrition prevents significant complication. Currently, investigations are directed at discovering useful neuroprotective agents that prevent secondary neurologic injury.
Brain Trauma Foundation, American Association of Neurological Surgeons, Joint Section on Neurotrauma and Critical Care. Guidelines for the management of severe head injury. J Neurotrauma. 1996;13:641-734.
2.
Fenstermacher JD. Flow of water and solutes across the blood brain barrier. In: Dacey RG, ed. Trauma of the Central Nervous System. New York: Raven Press;1985:123-140.
3.
Davson H, Hollingsworth G, Segal MB. The mechanism of drainage of the cerebrospinal fluid. Brain. 1970;93:665-678.
4.
Miller JD, Sullivan HG. Severe intracranial hypertension. Int Anesthesiol Clin. 1979;17(2,3):19-75.
5.
Powers W.Hemodynamics and metabolism in ischemic cerebrovascular disease. Neurol Clin. 1992;10:31-48.
6.
Powers W.Acute hypertension after stroke: the scientific basis for treatment decisions. Neurology. 1993;43:461-467.
7.
Strandgaard S.Autoregulation of cerebral blood flow in hyper-tensive patients. Circulation. 1976;53:720-727.
8.
Mchedlishvili G.Pathogenetic role of circulatory factors in brain edema development. Neurosurg Rev. 1988;11:7-13.
9.
Durward QJ, Del Maestro RF, Amacher AL, et al. The influence of systemic arterial pressure and intracranial pressure on the development of cerebral vasogenic edema. J Neurosurg. 1983;59:803-809.
10.
Prough DS, Dewitt DS. Cerebral protection. In: Chernow B, ed. The Pharmacologic Approach to the Critically Ill Patient, 3rd ed.Baltimore, MD: Williams and Wilkins; 1994:247-271.
11.
Grubb RL Jr, Raichle ME, Eichling JO, et al. The effects of changes in PaCO2 on cerebral blood volume, blood flow, and vascular mean transit time. Stroke. 1974;5:630-639.
12.
Lassen NA. Cerebral and spinal cord blood flow. In: Cottrell JE, Turndorf H, eds. Anesthesia and Neurosurg. St. Louis, MO: CV Mosby; 1980:1-24.
13.
Koehler RC, Traystman RJ. Bicarbonate ion modulation of cerebral blood flow during hypoxia and hypercapnia. Am J Physiol. 1982;243:H33-H40.
14.
Maximilian VA, Prohovnik I, Risberg J.Cerebral hemodynamic response to mental activation in norm- and hypercapnia. Stroke. 1980;11:342-347.
15.
Becker D, Remondino RL. Intracranial pressure monitoring. In: Shoemaker WC, Ayres S, Grenvik A, eds. Textbook of Critical Care. 2nd ed.Philadelphia, PA: W. B. Saunders; 1989:291-295.
16.
Miller JD, Butterworth JF, Gudeman SK, et al. Further experience in the management of severe head injury. J Neurosurg. 1981;54:289-299.
17.
Bouma GJ, Muizelaar JP, Choi SC, et al. Cerebral circulation and metabolism after severe traumatic brain injury: the elusive role of ischemia. J Neurosurg. 1991;75:685-693.
18.
Dewitt DS, Jenkins LW, Prough DS. Enhanced vulnerability to secondary ischemic insults after experimental traumatic brain injury. New Horizons. 1995;3:376-383.
19.
Johnston IH, Johnston JA, Jennet B.Intracranial-pressure changes after head injury. Lancet. 1970;ii:433-436.
20.
Miller JD, Butterworth JF, Gudeman SK, et al. Further experience in the management of head injury. Neurosurg. 1981;54:289-299.
21.
Baethmann A, Maier-Hauff K, Kempski O, et al. Mediators of brain edema and secondary brain damage. Crit Care Med. 1988;16:972-987.
22.
Cheung JY, Bonventre JV, Molis CD, et al. Calcium and ischemic injury. N Engl J Med. 1986;314:1670-1676.
23.
Choi D.Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1988;1:623-634.
24.
Maxwell WL, Povlishock JT, Graham DL. A mechanistic analysis of nondisruptive axonal injury: a review. J Neurotrauma. 1997;14:419-440.
25.
McCracken E, Hunter AJ, Patel S, et al. Calpain activation and cytoskeletal protein breakdown in the corpus callosum of the head-injured patients. J Neurotrauma. 1999;16:749-761.
26.
Kontos HA. Oxygen radicals in cerebral vascular injury. Circ Res. 1985;57:508-516.
27.
Siesjo BK, Agardh C-D, Bengtsson F. Free radicals and brain damage. Cerebrovasc Brain Metab Rev. 1989;1:165-211.
28.
Rothwell NJ, Strijbos PJ. Cytokines in neurodegeneration and repair. Int J Dev Neurosci. 1995;13:179-185.
29.
Yuan J, Yankner BA. Apoptosis in the nervous system. Nature. 2000;407:802-809.
30.
Teasdale G, Jennett B.Aspects of coma after severe head injury. Lancet. 1977;1:878-881.
31.
Teasdale G, Jennett B.Assessment of coma and impaired consciousness: a practical scale. Lancet. 1974;2:81.
32.
Lam AM, Winn HR, Cullen BF, et al. Hyperglycemia and neurological outcome in patients with head injury. J Neurosurg. 1991;75:545-551.
33.
Lang EW, Chesnutt RM. Intracranial pressure. Monitoring and management. Neurosurg Clin North Am. 1994;5:573-605.
34.
O’Sullivan MG, Statham PF, Jones PA, et al. Role of intracranial pressure monitoring in severely head injured patients without signs of intracranial hypertension on initial CT. J Neurosurg. 1994;80:46-50.
35.
Saul TG, Ducker TB. Effect of intracranial pressure monitoring and aggressive treatment on mortality in severe head injury. J Neurosurg. 1982;56:498-503.
36.
Narayan RK, Greenberg RP, Miller JD, et al. Improved confidence of outcome prediction in severe head injury: a comparative analysis of the clinical examination, multimodality evoked potentials, CT scanning and intracranial pressure. J Neurosurg. 1981;54:751-762.
37.
Marmarou A, Anderson RL, Ward JD, et al. Impact of ICP instability and hypotension on outcome in patients with severe head trauma. J Neurosurg. 1991;75:S59-S66.
38.
Narayan RK, Kishore PR, Becher DP, et al. Intracranial pressure: to monitor or not to monitor? A review of our experience with severe head injury. J Neurosurg. 1982;56:650-659.
39.
Clark WC, Muhlbauer MS, Lowrey R, et al. Complications of intracranial pressure monitoring in trauma patients. Neurosurgery. 1989;25:20-24.
40.
Chestnut RM, Marshall SB, Piek J, et al. Early and late systemic hypotension as a frequent and fundamental source of cerebral ischemia following severe brain injury in the Traumatic Coma Data Bank. Acta Neurochir Suppl (Wien). 1993;51:121-125.
41.
Pietropaoli JA, Rogers FB, Shackford SR, et al. The deleterious effects of intraoperative hypotension on outcome in patients with severe head injuries. J Trauma. 1992;33:403-407.
42.
Rosner MJ, Daughton S.Cerebral perfusion pressure management in head injury. J Trauma. 1990;30:933-941.
43.
McGraw CP. A cerebral perfusion pressure greater than 80 mm Hg is more beneficial. In: Hoff JT, Betz AL, eds. Intracranial Pressure VII. Berlin, Germany: Springer-Verlag; 1989:839-841.
44.
Changaris DG, McGraw CP, Richardson JD, et al. Correlation of cerebral perfusion pressure and Glasgow Coma Scale to outcome. J Trauma. 1987;27:1007-1013.
45.
Choi SC, Narayan RK, Anderson RL, et al. Enhanced specificity of prognosis in sever head injury. J Neurosurg. 1988;69:381-385.
46.
Marmarou A, Anderson RL, Ward JD, et al. Impact of ICP instability and hypotension on outcome in patients with severe head trauma. J Neurosurg. 1991:75:S159-S166.
47.
Andrews BT, Chiles BW, Olsen WL, et al. The effect of intracerebral hematoma location on the risk of brain-stem compression and on clinical outcome. J Neurosurg. 1988;69:518-522.
48.
Marshall LF, Barba D, Toole BM, et al. The oval pupil: clinical significance and relationship to intracranial hypertension. J Neurosurg. 1983;58:566-568.
49.
Zornow MH, Todd MM, Moore SS. The acute cerebral effects of changes in plasma osmolality and oncotic pressure. Anesthesiology. 1987;67:936-941.
50.
Tommasino C, Moore S, Todd MM. Cerebral effects of isovolemic hemodilution with crystalloid or colloid solutions. Crit Care Med. 1988;16:862-868.
51.
Poole GV Jr, Prough DS, Johnson JC, et al. Effects of resuscitation from hemorrhagic shock on cerebral hemodynamics in the presence of an intracranial mass. J Trauma. 1987;27:18-23.
52.
Walsh JC, Zhoung J, Shackford SR. A comparison of hypertonic to isotonic fluid in the resuscitation of brain injury and hemorrhagic shock. J Surg Res. 1991;50:284-292.
53.
Battistella Fd, Winer DH. Combined hemorrhagic shock and head injury: effects of hypertonic saline (7.5%) resuscitation. J Trauma. 1991;31:182-188.
54.
Wisner DH, Schuster L, Quinn C.Hypertonic saline resuscitation of head injury: effects on cerebral water content. J Trauma. 1990;30:75-78.
55.
Vassar MJ, Fischer RR, O’Brien PE, et al. A multicenter trial for resuscitation of injured patients with 7.5% sodium chloride. The effect of added dextran 70. The Multicenter Group for the Study of Hypertonic Saline in Trauma Patients. Arch Surg. 1993;128:1003-1011.
56.
Vassar MJ, Perry CA, Holcroft JW. Prehospital resuscitation of hypotensive trauma patients with 7.5% NaCl versus 7.5% NaCl with added dextran: a controlled trial. J Trauma. 1993;34:622-632.
57.
Younes RN, Aun F, Accioly CQ, et al. Hypertonic solution in the treatment of hypovolemic shock: a prospective, randomized study in patients admitted to the emergency room. Surgery. 1992;111:380-385.
58.
Mattox KL, Maningas PA, Moore EE, et al. Prehospital hypertonic saline/dextran infusion for post-traumatic hypotension. The U.S.A. Multicenter Trial. Ann Surg. 1991;213:482-491.
59.
Borel C, Hanley D, Diringer MN, et al. Intensive management of severe head injury. Chest. 1990;98:180-189.
Brown FD, Hanlon K, Crochard A, et al. Effects of sodium nitropurusside on cerebral blood flow in conscious human beings. Surg Neurol. 1977;7:67-70.
62.
Cottrell JE, Gupta B, Rappoport H, et al. Intracranial pressure during nitroglycerin-induced hypotension. J Neurosurg. 1980;53:309-311.
63.
Vorstrup S, Anderson A, Blegvad N, et al. Calcium antagonist (PY108-068) treatment may further decrease flow in ischemic areas in acute stroke. J Cereb Blood Flow Metab. 1986;6:222-229.
64.
Hayek DA, Veremakis C.Physiologic concerns during brain resuscitation. In: Civetta JM, Taylor RW, Kirby RR, eds. Critical Care, 2nd ed.Philadelphia: JB Lippincott; 1992:1449-1466.
65.
Waldemar G, Schmidt JF, Andersen AR, et al. Angiotensin converting enzyme inhibition and cerebral blood flow autoregulation in normotensive and hypertensive man. J Hypertens. 1989;7:229-235.
66.
Robertson CS, Contant CF, Gokaslan ZL, et al. Cerebral blood flow, arteriovenous oxygen difference, and outcome in head-injured patients. J Neurol Neurosurg Psychiatry. 1992;55:594-603.
67.
Bouma GJ, Muizelaar JP, Stringer WA, et al. Ultra early evaluation of regional cerebral blood flow in severely head injured patients using xenon enhanced computed tomography. J Neurosurg. 1992;77:360-368.
68.
Jaggi JL, Obrist WD, Gennarelli TA, et al. Relationship of early cerebral blood flow and metabolism to outcome in acute head injury. J Neurosurg. 1990;72:176-182.
69.
Marion DW, Darby J, Yonas H.Acute regional cerebral blood flow changes caused by severe head injuries. J Neurosurg. 1991;74:407-414.
70.
Rosner MJ. Cerebral perfusion pressure: link between intracranial pressure and systemic circulation. In: Wood JH, ed. Cerebral Blood Flow. Physiologic and Clinical Aspects. New York, NY: McGraw-Hill; 1987:425-488.
71.
Feldman Z, Kanter MJ, Robertson CS, et al. Effect of head elevation on intracranial pressure, cerebral perfusion pressure, and cerebral blood flow in head-injured patients. J Neurosurg. 1992;76:207-211.
72.
Meixenberger J, Baunach S, Amschler J, et al. Influence of body position on tissue-pO2, cerebral perfusion pressure in patients with acute brain injury. Neurol Res. 1997;19:249-253.
73.
Davenport A, Will EJ, Davison AM. Effect of posture on intracranial pressure and cerebral perfusion pressure in patients with fulminant hepatic and renal failure after acetaminophen self-poisoning. Crit Care Med. 1990;18:286-289.
74.
Durward QJ, Amacher AL, Del Maestro RF, et al. Cerebral and cardiovascular responses to changes in head elevation in patients with intracranial pressure. J Neurosurg. 1988;69:15-23.
75.
Busto R, Globus MY, Dietrich WD, et al. Small differences in intraischemic brain temperature critically determine extent of ischemic neuronal injury. J Cereb Blood Flow Metab. 1987;7:729-738.
76.
Busto R, Globus MY, Dietrich WD, et al. Effect of mild hyperthermia on ischemia-induced release of neurotransmitters and free fatty acids in rat brain. Stroke. 1989;20:904-910.
77.
Kuboyama K, Safar P, Tisherman SA, et al. Delay in cooling negates the beneficial effects of mild resuscitative cerebral hypothermia after cardiac arrest in dogs: a prospective, randomized study. Crit Care Med. 1993;21:1348-1353.
78.
Weinrauch V, Safar P, Tisherman SA, et al. Beneficial effect of mild hypothermia and detrimental effect of deep hypothermia after cardiac arrest in dogs. Stroke. 1992;23:1454-1462.
79.
Metz C, Holzchuh M, Bein T, et al. Moderate hypothermia in patients with severe injury: cerebral and extracerebral effects. J Neurosurg. 1996;85:533-541.
80.
Marion DW, Obrist WD, Carlier PM, et al. The use of moderate therapeutic hypothermia for patients with severe head injuries: a preliminary report. J Neurosurg. 1993;79:354-362.
81.
Shiozaki T, Sugimoto H, Taneda M, et al. Effect of mild hypothermia on uncontrollable intracranial hypertension after severe head injury. J Neurosurgery. 1993;79:363-368.
82.
Shiozaki T, Kato A, Taneda M, et al. Little benefit from mild hypothermia therapy for severely head injured patients with low intracranial pressure. J Neurosurg. 1999;91:185-191.
83.
Prelipp RC, Coursin DB. Sedative and neuromuscular blocking drug use in critically ill patients with head injuries. New Horizons. 1995;3:456-468.
84.
Mirski MA, Muffelman B, Ulatowski JA, et al. Sedation for the critically ill neurologic patient. Crit Care Med. 1995;23:2038-2053.
85.
Cotev S, Shelit MN. Effects of diazepam on cerebral blood flow and oxygen uptake after head injury. Anesthesiology. 1975;43:117-122.
86.
McCammon RL, Hilgenberg JC, Stoeling RK. Hemodynamic effects of diazepam-nitrous oxide in patients with coronary artery disease. Anesth Analg. 1980;59:438-441.
87.
Forster A, Juge O, Morel D.Effects of midazolam on cerebral blood flow in human volunteers. Anesthesiology. 1982;56:453-455.
88.
Fleischer JE, Milde JH, Moyer TP, et al. Cerebral effects of high dose midazolam and subsequent reversal with Ro15-7888 in dogs. Anesthesiology. 1988;68:234-242.
89.
Tateishi A, Tsuyoshi M, Takeshita H, et al. Diazepam and intracranial pressure. Anesthesiology. 1981;54:335-337.
90.
Malacrida R, Fritz ME, Suter PM, et al. Pharmacokinetics of midazolam administered by continuous infusion to intensive care patients. Crit Care Med. 1992;20:1123-1126.
91.
Barrientos-Vega R, Mar Sanchez-Soria M, Morales-Garcia C, et al. Prolonged sedation of critically ill patients with midazolam or propofol: impact on weaning and costs. Crit Care Med. 1997;25:33-40.
92.
Riker RR, Picard JT, Fraser GL. Prospective evaluation of the sedation-agitation scale for adult critically ill patients. Crit Care Med. 1999;27:1325-1329.
93.
Devlin JW, Boleski G, Mlynarek M, et al. Motor activity assessment scale: a valid and reliable sedation scale for use with mechanically ventilated patients in an adult surgical intensive care unit. Crit Care Med. 1999;27:1271-1275.
94.
Kollef MH, Levy NT, Ahrens TS, et al. The use of continuous IV sedation is associated with prolongation of mechanical ventilation. Chest. 1998;114:541-548.
95.
Weinbroum AA, Halpern P, Rudick V, et al. Midazolam versus propofol for long term sedation in the ICU: a randomized prospective comparison. Intensive Care Med. 1997;23:1258-1263.
96.
Wagner BKJ, O’Hara DA, Hammond JS. Drugs for amnesia in the ICU. Am J Crit Care. 1997;6:192-201.
97.
Farling PA, Johnston JR, Coppel DL. Propofol infusion for sedation of patients with head injuries in intensive care. Anaesthesia. 1989;44:222-226.
98.
Herregods L, Verbeke J, Rolly G, et al. Effect of propofol on elevated intracranial pressure. Preliminary results. Anaesthesia. 1988;43(suppl):107-109.
99.
Stephan H, Sonntag H, Schenk HD, et al. Effects of propofol on cerebral blood flow, cerebral oxygen consumption and cerebral vascular reactivity. Anaesthesist. 1987;36:60-65.
100.
Mackenzie SJ, Kapadia F, Grant IS. Propofol infusion for control of status epilepticus. Anaesthesia. 1990;45:1043-1045.
101.
Avramov MN, Husain MM, White PF. The comparative effects of methohexital, propofol, and etomidate for electroconvulsive therapy. Anesth Analg. 1995;81:596-602.
102.
Kowalski SD, Rayfield CA. A post hoc descriptive study of patients receiving propofol. Am J Crit Care. 1999;8:507-513.
103.
Bailie GR, Cockshott ID, Douglass EJ, et al. Pharmacokinetics of propofol during and after long term continuous infusion for maintenance of sedation in ICU patients. Br J Anaesth. 1992;68:486-491.
104.
Harris CE, Grounds RM, Murray AM, et al. Propofol for long term sedation in the intensive care unit. Anaesthesia. 1990;45:366-372.
105.
Todd MM, Warner DS. Neuroanesthesia: a critical review. In: Rogers MC, Tinker JH, Covino BG, et al, eds. Priniciples and Practice of Anesthesia. St. Louis, MO: Mosby; 1993:1599-1643.
106.
Scwedler M, Miletich DJ, Albrecht RF. Cerebral blood flow and metabolism following ketamine administration. Can Anaesthetist Soc J. 1982;29:222-226.
Kochs E, Werner C, Hoffman WE, et al. Concurrent increases in brain electrical activity: intracranial blood flow velocity during low dose ketamine anaesthesia. Can J Anaesth. 1991;38:826-830.
109.
Lanier WL, Perkins WJ, Karlsson BR, et al. The effects of dizocilpine maleate (MK-801), an antagonist of the N-methyl-D-aspartate receptor, on neurological recovery and histopathology following complete cerebral ischemia in primates. J Cereb Blood Metab. 1990;10:252-261.
110.
Church J, Zeman S, Lodge S.The neuroprotective action of ketamine and MK801 after transient cerebral ischemia in rats. Anesthesiology. 1988;69:702-709.
111.
Shapira Y, Artru A, Lam A.Ketamine decreases cerebral infarct volume and improves neurological outcome following experimental head trauma in rats. J Neurosurg Anesthesiol. 1992;4:231-240.
112.
Shapiro HM, Wyte SR, Harris AB. Ketamine anaesthesia in patients with intracranial pathology. Br J Anaesth. 1972;44:1200-1204.
113.
White PF, Way WL, Trevor AJ. Ketamine—Its pharmacology and therapeutic uses. Anesthesiology. 1982;56:119-136.
114.
Ferrer-Allado T, Brechner VL, Dymond A, et al. Ketamine induced electroconvulsive phenomena in the human limbic and thalamic regions. Anesthesiology. 1973;38:333-344.
115.
Davis DW, Mans AM, Biebuyck JF, et al. Regional brain glucose utilization during etomidate anesthesia. Anesthesiology. 1986;64:751-757.
116.
Milde LN, Milde JH, Michenfelder JD. Cerebral, functional, metabolic, and hemodynamic effects of etomidate in dogs. Anesthesiology. 1985;63:371-377.
117.
Ledingham ImcA, Watt J.Influence of sedation on mortality in critically ill multiple trauma patients. Lancet. 1983;i:1270.
118.
Albanese J, Viviand X, Potie F, et al. Sufentanil, fentanyl, and alfentanil in head trauma patients: a study on cerebral hemodynamics. Crit Care Med. 1999;27:407-411.
119.
Sperry RJ, Bailey PL, Reichman MV, et al. Fentanyl and sufentanil increase intracranial pressure in head trauma patients. Anesthesiology. 1992;77:414-420.
120.
Nadal M, Munar F, Poca M, et al. Cerebral hemodynamic effects of morphine and fentanyl in patients with severe head injury: absence of correlation to cerebral autoregulation. Anesthesiology. 2000;92:11-19.
121.
Tipps LB, Coplin WM, Murry KR, et al. Safety and feasibility of continuous infusion of remifentanil in the neurosurgical intensive care unit. Neurosurgery. 2000;46:596-602.
122.
Warner DS, Hindman BJ, Todd MM, et al. Intracranial pressure and hemodynamic effects of remifentanil versus alfentanil in patients undergoing supratentorial craniotomy. Anesth Analg. 1996;83:348-353.
123.
Baker KZ, Ostapkovich N, Mack PF, et al. Cerebral blood flow reactivity is similar during remifentanil/N2O and fentanyl/N2O anesthesia. Anesthesiology. 1996;85:A180(abstract).
124.
Baker KZ, Ostapkovich N, Sisti MB, et al. Intact cerebral blood flow reactivity during remifentanil/nitrous oxide anesthesia. J Neurosurg Anesthesiol. 1997;9:134-140.
125.
Guy J, Hindman BJ, Baker KZ, et al. Comparison of remifentanil and fentanyl in patients undergoing craniotomy for supratentorial space occupying lesions. Anesthesiology. 1997;86:514-524.
126.
Ochial C, Asano T, Takakura K, et al. Mechanisms of cerebral protection by pentobarbital and nizofenane correlated with the course of local cerebral blood flow changes. Stroke. 1982;13:788-796.
127.
Kassell NF, Hitchar PW, Gerk MK, et al. Alterations in cerebral blood flow, oxygen metabolism and electrical activity produced by high dose thiopental. Neurosurgery. 1980;7:598-603.
Smith AL. Barbiturate protection in cerebral hypoxia. Anesthesiology. 1977;47:285-293.
130.
Majeroska MD, Strosznajder J, Lazarewicezj J.Effect of ischemic anoxia and barbiturate anesthesia on free radical oxidation of mitochondrial phospholipids. Brain Res. 1978;158:423-434.
131.
Smith DS, Rehncrona S, Siesjo BK. Inhibitory effects of different barbiturates on lipid peroxidation in brain tissue in vitro. Anesthesiology. 1980;53:186-194.
132.
Nordstrom CH, Messeter K, Sundbarg G.Cerebral blood flow, vasoreactivity and oxygen consumption during barbiturate therapy in severe traumatic brain lesions. J Neurosurg. 1988;68:424-431.
133.
Marshall LF, Smith RW, Shapiro HM. The outcome with aggressive treatment in severe head injuries. Part II: acute and chronic barbiturate administration in the management of head injuries. J Neurosurg. 1979;50:26-30.
134.
Rea GL, Rockswold GL. Barbiturate therapy in uncontrolled intracranial hypertension. Neurosurgery. 1983;12:401-404.
135.
Eisenberg HM, Frankowski RF, Contant CF. High-dose barbiturate control of elevated intracranial pressure in patients with severe head injury. J Neurosurg. 1988;69:15-23.
136.
Schwartz ML, Tator CH, Rowed DW, et al. The University of Toronto Head Injury Treatment Study: a prospective, randomized comparison of pentobarbital and mannitol. Can J Neurol Sci. 1980;11:434-440.
137.
Ward JD, Becker DP, Miller JD. Failure of prophylactic barbiturate coma in the treatment of severe head injury. J Neurosurg. 1985;62:383-388.
138.
Ghajar J, Hariri RJ, Narayan RK, et al. Survey of critical care management of comatose, head-injured patients in the United States. Crit Care Med. 1995;23:560-567.
139.
Bricolo A, Formenton A, Turella G, et al. Clinical and EEG effects of mechanical hyperventilation in acute traumatic coma. Eur Neurol. 1972;8:219-224.
Sheinberg M, Kanter MJ, Robertson CS, et al. Continuous monitoring of jugular venous oxygen saturation in head injured patients. J Neurosurg. 1992;76:212-217.
142.
Obrist WD, Langfitt TW, Jaggi JL, et al. Cerebral blood flow and metabolism in comatose patients with acute head injury. J Neurosurg. 1984;61:241-253.
143.
Fortune JB, Feustel PJ, Graca L, et al. Effect of hyperventilation, mannitol, and ventriculostomy drainage on cerebral blood flow after head injury. J Trauma. 1995;39:1091-1099.
144.
Rudis MI, Guslits BJ, Peterson EL, et al. Economic impact of prolonged motor weakness complicating neuromuscular blockade in the intensive care unit. Crit Care Med. 1996;24:1749-1756.
145.
Hsiang JK, Chesnut RM, Crisp CP, et al. Early, routine paralysis for intracranial pressure control in severe head injury: is it necessary?Crit Care Med. 1994;22:1471-1476.
146.
Segredo V, Caldwell JE, Matthay MA, et al. Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med. 1992;327:524-528.
147.
Hoyt JW. Persistent paralysis in critically ill patients after the use of neuromuscular blocking agents in critical care. New Horizons. 1994;2:48-55.
148.
Watling SM, Dasta JF. Prolonged paralysis in intensive care unit patients after the use of neuromuscular blocking agents: a review of the literature. Crit Care Med. 1994;2:34-47.
149.
Rudis MI, Sikora CA, Angus E, et al. A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients. Crit Care Med. 1997;25:575-583.
150.
Kassel NF, Baumann KW, Hitchon PW, et al. The effect of high dose mannitol on cerebral blood flow in dogs with normal intracranial pressure. Stroke. 1982;13:59-61.
151.
Muizelaar JP, Wei EP, Kontos HA, et al. Mannitol causes compensatory cerebral vasoconstriction and vasodilatation to blood viscosity changes. J Neurosurg. 1983;59:822-828.
152.
Muizelaar JP, Lutz HA, Becker DP. Effect of mannitol on ICP and CBF and correlation with pressure autoregulation in severely head injured patients. J Neurosurg. 1984;61:700-706.
153.
Barry KG, Berman AR. Mannitol infusion. Part III: the acute effect of the intravenous infusion of mannitol on blood and plasma volume. N Engl J Med. 1961;264:1085-1088.
154.
Rosner MJ, Coley I.Cerebral perfusion pressure: a hemodynamic mechanism of mannitol and the pre-mannitol hemogram. Neurosurgery. 1987;21:147-156.
155.
Burke AM, Quest DO, Chien S, et al. The effects of mannitol on blood viscosity. J Neurosurg. 1981;55:550.
156.
James HE. Methodology for the control of intracranial pressure with hypertonic mannitol. Acta Neurochir. 1980;51:160-172.
157.
Mendelow AD, Teasdale GM, Russell T, et al. Effect of mannitol on cerebral blood flow and cerebral perfusion pressure in human head injury. J Neurosurg. 1985;63:43-48.
158.
Miller JD. Clinical management of cerebral edema. Br J Hosp Med. 1979;20:152-166.
159.
Miller JD, Leach PJ. Assessing the effects of mannitol and steroid therapy on intracranial volume/pressure relationships. J Neurosurg. 1975;42:274-281.
160.
Feig PU, McCurdy DK. The hypertonic state. N Engl J Med. 1977;297:1499.
161.
Shackford S, Norton C, Todd M.Renal, cerebral and pulmonary effects of hypertonic resuscitation in a porcine model of hemorrhagic shock. Surgery. 1988;104:553-557.
162.
Smith HP, Kelly DL, McWhorter JM, et al. Comparison of mannitol regimens in patients with severe head injury undergoing intracranial monitoring. J Neurosurg. 1986;65:820-824.
163.
Becker DP, Vries JK. The alleviation of increased intracranial pressure by the chronic administration of osmotic agents. In: Brock M, Dietz H, eds. Intracranial Pressure. New York, NY: Springer; 1972:309-315.
164.
Cottrell JE, Rebustelli A, Post K, et al. Furosemide and mannitol induces changes in intracranial pressure and serum osmolarity and electrolytes. Anesthesiology. 1977;47:28-30.
165.
Heifetz MD. ICP reduction with furosemide and mannitol. J Neurosurg. 1987;67:475.
166.
Roberts PA, Pollay M, Engles C, et al. Effect on intracranial pressure of furosemide combined with varying doses and administration rates of mannitol. J Neurosurg. 1987;66:440-446.
167.
Wilkinson HA, Wepsic JG, Austin G.Diuretic synergy in the treatment of acute experimental cerebral edema. J Neurosurg. 1977;34:203-208.
168.
Todd MM, Tommasino C, Moore S.Cerebral effects of isovolemic hemodilution with a hypertonic saline solution. J Neurosurg. 1985;63:944-948.
169.
Gunnar W, Jonasson O, Merlotti G, et al. Head injury and hemorrhagic shock: studies of the blood brain barrier and intracranial pressure after resuscitation with normal saline, 3% saline solution, and dextran-40. Surgery. 1988;103:398-407.
170.
Gunnar WP, Merlotti GJ, Jonasson O, et al. Resuscitation from hemorrhagic shock: alterations of the intracranial pressure after normal saline, 3% saline and dextran-40. Ann Surg. 1986;204:686-692.
171.
Shackford SR, Zhuang J, Schmoker J.Intravenous fluid tonicity: effect on intracranial pressure, cerebral blood flow, and cerebral oxygen delivery in focal brain injury. J Neurosurg. 1992;76:91-98.
172.
Zornow MH. Hypertonic saline as a safe and efficacious treatment of intracranial hypertension. J Neurosurg Anesthesiol. 1996;8:175-177.
173.
Fisher B, Thomas D, Peterson B.Hypertonic saline lowers raised intracranial pressure in children after head trauma. J Neurosurg Anesthesiol. 1992;4:4-10.
174.
Worthley LI, Cooper DJ, Jones N.Treatment of resistant intracranial hypertension with hypertonic saline. Report of two cases. J Neurosurg. 1988;68:478-481.
175.
Qureshi AI, Suarez JI, Bhardwaj A, et al. Use of hypertonic (3%) saline/acetate infusion in the treatment of cerebral edema: effect on intracranial pressure and lateral displacement of the brain. Crit Care Med. 1998;26:440-446.
176.
Shenkin HA, Bezier HS, Bouzarth WF. Restricted fluid intake: rational management of the neurosurgical patient. J Neurosurg. 1976;45:432-436.
177.
Chesnut RM, Marshall LF, Klauber MR, et al. The role of secondary brain injury in determining outcome from severe head injury. J Trauma. 1993;34:216-222.
178.
Jelsma LF, McQueen JD. Effect of experimental water restriction on brain water. J Neurosurg. 1967;26:35-40.
179.
Schmoker JD, Shackford SR, Wald SL, et al. An analysis of the relationship between fluid and sodium administration and intracranial pressure after head injury. J Trauma. 1992;33:476-481.
180.
Galicich JH, French LA. Use of dexamethasone in the treatment of cerebral edema resulting from brain tumors and brain surgery. Am Pract. 1961;12:169-174.
181.
Bracken MB, Sheppard MJ, Collins WF Jr, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury. Results of the second National Acute Spinal Cord Injury Study. N Engl J Med. 1990;322:1405-1411.
182.
Dearden NM, Gibson JS, McDowall DG, et al. Effect of high-dose dexamethasone on outcome from severe head injury. J Neurosurg. 1986;64:81-88.
183.
Braackman R, Schouten HJA, van Dishoeck MB, et al. Megadose steroids in severe head injury: results of a double-blind clinical trial. J Neurosurg. 1983;58:326-330.
184.
Cooper PR, Moody S, Clark WK, et al. Dexamethasone and severe head injury: a prospective double-blind study. J Neurosurg. 1979;51:307-316.
185.
Giannotta SL, Weiss MH, Apuzzo MLJ, et al. High-dose glucocorticoids in the management of severe head injury. Neurosurgery. 1984;15:497-501.
186.
Saul TG, Ducker TB, Salcman M, et al. Steroids in severe head injury: a prospective randomized clinical trial. J Neurosurg. 1981;54:596-600.
187.
Gudeman SK, Miller JD, Becker DP. Failure of high-dose steroid therapy to influence intracranial pressure in patients with severe head injury. J Neurosurg. 1979;51:301-306.
188.
Papo I, Caruselli G, Luongo A.CSF withdrawal for the treatment of intracranial hypertension in acute head injuries. Acta Neurochir (Wein). 1981;56:191-199.
189.
Faraci FM, Mayhan WG, Heistad DD. Vascular effects of acetazolamide on the choroid plexus. J Pharmacol Exp Ther. 1990;254:23-27.
190.
Temkin NR, Haglund MM, Winn HR. Causes, prevention, and treatment of post-traumatic epilepsy. New Horizons. 1995;3:518-522.
Pohlmann-Eden B, Bruchmeir J.Predictors and dynamics of posttraumatic epilepsy. Acta Neurol Scand. 1997;95:257-262.
193.
Barry E, Bergey GK, Krumholtz A, et al. Posttraumatic seizure types vary with the interval after head injury. Epilepsia. 1997;38(suppl. 8):49S-50S.
194.
Angeleri F, Majkowski J, Cacchio G, et al. Posttraumatic epilepsy risk factors: one-year prospective study after head injury. Epilepsia. 1999;40:1222-1230.
195.
Asikaninen I, Kaste M, Sarna S.Early and late posttraumatic seizures in traumatic brain injury rehabilitation patients: brain injury factors causing late seizures and influence of seizures on long-term outcome. Epilepsia. 1999;40:584-589.
196.
Temkin NR, Dikmen SS, Wilensky AJ, et al. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med. 1990;323:497-502.
197.
McKinney RA, Debanne D, Gahwiler BH, et al. Lesion-induced axonal sprouting and hyperexcitability in the hippocampus in vitro: implications for the genesis of posttraumatic epilepsy. Nat Med. 1997;3:990-996.
198.
Bush PC, Prince DA, Miller KD. Increased pyramidal excitability and NMDA conductance can explain posttraumatic epileptogenesis without disinhibition: a model. J Neurophysiol. 1999;82:1754-1758.
199.
Graham DI, Ford I, Adams JH, et al. Ischemic brain damage is still common in fatal non-missile head injury. J Neurol Neurosurg Psychiatry. 1989;52:346-350.
200.
Chesnut RM, Marshall LF, Marshall SB. Medical management of intracranial pressure. In: Cooper PR, ed. Head Injury. Baltimore, MD: Williams and Wilkins; 1993:225-246.
201.
Treiman DM. Special treatment problems in adults. In: Smith DB, ed. Epilepsy: Current Approaches to Diagnosis and Treatment. New York: Raven Press; 1990:155-172.
202.
Glotzner FL, Haubitz I, Miltner F, et al. Seizure prevention using carbamazepine following severe brain injuries. Neurochirurgia (Stuttg). 1983;26:66-79.
203.
Anderson GD, Gidal BE, Hendryx RJ, et al. Decreased plasma protein binding of valproate in patients with acute head trauma. Br J Pharmacol. 1994;37:559-562.
204.
Griebel ML. Phenytoin protein binding in pediatric patients with acute traumatic injury. Crit Care Med. 1990;18:385-391.
205.
Rivey MP, Allington DR, Stone JD, et al. Alteration of carbamazepine pharmacokinetics in patients with traumatic brain injury. Brain Inj. 1995;9:41-47.
206.
Wohns RNW, Wyler AR. Prophylactic phenytoin in severe head injuries. J Neurosurg. 1973;38:155-158.
207.
Weiss GH, Feeney DM, Caveness WF, et al. Prognostic factors for the occurrence of posttraumatic epilepsy. Arch Neurol.1983;40:7-10.
208.
Roberts PR. Nutrition in the head-injured patient. New Horizons. 1995;3:506-517.
209.
Clifton GL, Robertson CS, Grossman RG, et al. The metabolic response to severe head injury. J Neurosurg. 1984;60:687-696.
210.
Dempsey DT, Guenter P, Mullen JL, et al. Energy expenditure in acute trauma to the head with and without barbiturate therapy. Surg Gynecol Obstet. 1985;160:128-134.
211.
Robertson CS, Clifton GL, Grossman RG, et al. Oxygen utilization and cardiovascular function in head-injured patients. J Neurosurg. 1984;15:307-314.
212.
Bruder N, Dumon JC, Francois G.Evolution of energy expenditure and nitrogen excretion in severe head-injured patients. Crit Care Med. 1991;19:43-48.
213.
Bivins B, Twyman D, Young B.Failure of non-protein calories to mediate protein conservation in brain-injured patients. J Trauma. 1986;26:980-986.
214.
Twyman D, Young AB, Ott L, et al. High protein enteral feedings: a means of achieving positive nitrogen balance in head injured patients. J Perenter Eneral Nutr. 1985;9:679-684.
215.
Clifton GL, Robertson CS, Contant CF. Enteral hyperalimentation in head injury. J Neurosurg. 1985;62:186-193.
216.
Young B, Ott L, Norton J, et al. Metabolic and nutritional sequelae in the non-steroid treated head injury patient. Neurosurgery. 1985;17:784-791.
217.
Rowlands B, Hunt D, Roughneen P, et al. Intravenous and enteral nutrition with branched chain amino acid enriched products following multiple trauma with closed head injury. J Perenter Eneral Nutr. 1986;10(suppl):4S.
218.
Ott LG, Schmidt JJ, Young AB, et al. Comparison of administration of two standard intravenous amino acid formulas to severely brain-injured patients. Drug Intell Clin Pharm. 1988;22:763-768.
219.
Rapp RP, Young B, Twyman D, et al. The favorable effect of early parenteral feeding on survival in head-injured patients. J Neurosurg. 1983;58:906-912.
220.
Young B, Ott L, Twyman D, et al. The effect of nutritional support on outcome from severe head injury. J Neurosurg. 1987;67:668-676.
221.
Grahm TW, Zadrozny DB, Harrington T.The benefits of early jejunal hyperalimentation in the head-injured patient. Neurosurgery. 1989;25:729-735.
222.
Kirby DF, Clifton GL, Turner H, et al. Early enteral nutrition after brain injury by percutaneous endoscopic gastrojejunostomy. J Perenter Eneral Nutr. 1991;15:298-302.
223.
Smith DH, Casey K, McIntosh TK. Pharmacologic therapy for traumatic brain injury: experimental approaches. New Horizons. 1995;3:562-572.
224.
Shapira Y, Yadid G, Coten S, et al. Protective effect of MK-801 in experimental brain injury. J Neurotrauma. 1990;7:131-139.
225.
McIntosh TK, Vink R, Yamakami I, et al. Magnesium deficiency exacerbates and pretreatment improves outcome following traumatic brain injury in rats. Magnetic resonance spectroscopy and behavioral studies. J Neurotrauma. 1988;5:17-31.
226.
McIntosh TK, Vink R, Yamakami I, et al. Magnesium protects against neurological deficit after brain injury. Brain Res. 198;482:252-260.
227.
Okiyama K, Smith DH, Gennarelli TA, et al. The sodium channel blocker and glutamate release inhibitor BW10003C87 and magnesium attenuate regional cerebral edema following experimental brain injury in the rat. J Neurochem. 1995;64:802-809.
228.
Glatt BS, Raghupathi R, Gennarelli TA, et al. Effect of simultaneous blockade of opiate and glutamate receptors on neurobehavioral outcome following experimental brain injury. J Neurotrauma. 1995;12:118.
229.
Kemp JA, Foster AC, Wong EHF. Non-competitive antagonists of excitatory amino acid receptors. Trends Neurosci. 1987;10:294-298.
230.
Shohami E, Novikov M, Mechoulam R.A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat. J Neurotrauma. 1993;10:109-119.
231.
Hylton C, Perri B, Voddi M, et al. Non-NMDA antagonist GYKI 52466 enhances spatial memory after experimental brain injury. J Neurotrauma. 1995;12:124.
232.
Marshall LF. Head injury: recent past, present, and future. Neurosurgery. 2000;47:546-561.
233.
Braughler J, Pregenzer J, Chase R, et al. Novel 21-aminosteroids as potent inhibitors of iron-dependent lipid peroxidation. J Biol Chem. 1987;262:10434-10440.
234.
Marshall LF, Maas AI, Marshall SB, et al. A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury. J Neurosurg. 1998;89:519-525.
235.
Huang H, Patel PB, Salahudeen AK. Lazaroid compounds prevent early but not the late stages of oxidant induced cell injury. Potential explanation for the lack of efficacy of lazaroid in clinical trials. Pharmacol Res. 2001;43:55-61.
236.
Young B, Runge JW, Waxman KS, et al. Effects of pegorgotein on neurologic outcome of patients with severe head injury: a multicenter, randomized controlled trial. JAMA. 1996;276:538-543.
237.
Johnson EM, Greenlund LJS, Atkins PT, et al. Neuronal apoptosis: current understanding of molecular mechanisms and potential role in ischemic brain injury. J Neurotrauma. 1995;12:843-852.
238.
Huang PP, Esquenazi S, Le Roux PD. Cerebral cortical neuron apoptosis after mild excitotoxic injury in vitro: different roles of mesencephalic and cortical astrocytes. Neurosurgery. 1999;45:1413-1422.
